Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Human Genome Sciences, Inc. (HGSI) Reports Progress With Several Late-Stage Products

In a statement, ahead of an investors meeting in New York Wednesday, Rockville-based Human Genome Sciences reported significant progress for three late-stage products. The company said the drug Albuferon for hepatitis C and LymphoStat-B for lupus are on track for potential launch in 2010.

Also on the list is Abthrax for inhalation anthrax treatment. It is on track to begin delivery this fall. Human Genome also has an agreement with Glaxo Smith Kline to advance darapladib to Phase 3 testing for the treatment of atherosclerosis. Human Genome Sciences also said it and Glaxo Smith Kline have agreed to initiate a Phase 2 trial of LymphoStat-B for use in the treatment of multiple sclerosis.

“In June 2006, the U.S. Government exercised its option to purchase 20,000 doses of ABthrax for the Strategic National Stockpile,” the company said in a statement. “The purchase award was made under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Stockpile. HGS expects to receive $165 million in revenue from the award. In addition, there is potential for future orders for ABthrax from the U.S. Government or from other governments friendly to the U.S.”

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *